VivoSeq
Neurology

Cognitive Impairment

242

Pipeline Programs↗

42

Active Trials↗

88

Companies Involved↗

Cognitive impairment is a highly competitive landscape with 242 programs across 88 companies. The most active players are Lundbeck, Nxera Pharma UK Limited, High Point Pharmaceuticals, LLC.. 47 therapies are approved with 26 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

83/100

Pipeline Velocity

41/100

Mech. Concentration

4/100

Completion Rate

71/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Lundbeck logo

Lundbeck

2 programs

Phase 1N

Nxera Pharma UK Limited

1 program

Phase 1H

High Point Pharmaceuticals, LLC.

1 program

Phase 1Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.

1 program

Phase 1K

Keymed Biosciences Co.Ltd

1 program

Phase 1V

Validus Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

253 of 268 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody52%Protein / enzyme41%Radiopharmaceutical2<1%Peptide1<1%Cell therapy1<1%Gene therapy1<1%Other1<1%

Small molecule leads; the ring shows all 268 classified programs, each share of the total. Modality classified for 99% of 280 pipeline programs.

Analysis

Trial Status

260

clinical trials

Completed131 · 50%
Terminated36 · 14%
Unknown status34 · 13%
Recruiting24 · 9%
Withdrawn15 · 6%
Not yet recruiting11 · 4%
Other9 · 3%

Clinical Trials

Trial Activity

260 trials

Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia
Recruiting·FFirst People's Hospital of Shenyang·N/A·NCT06507488·206 enrolled
The Study of Ginkgo Leaf Dropping Pills and Huperzine a Injection Combined with Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury
Recruiting·WWanbangde Pharmaceutical Group Co., LTD·Phase 4·NCT06704334·50 enrolled
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
Recruiting·MMclean Hospital·Phase 1·NCT04075435·12 enrolled
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
Recruiting·JJYAMS PET Research & Development Limited·Phase 3·NCT07422857·316 enrolled
Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy
Recruiting·—·Phase 2·NCT06051240·84 enrolled
Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease
Recruiting·MMedical University of Lodz·Phase 2·NCT06850597·30 enrolled
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
Recruiting·OOregon Health and Science University·Phase 1·NCT05591027·48 enrolled
Metformin Treatment on Cognitive Impairment of Schizophrenia
Recruiting·—·Phase 3·NCT05838573·120 enrolled
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Recruiting·JJohns Hopkins University·Phase 1·NCT04123314·20 enrolled
Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)
Recruiting·HHospital Moinhos de Vento·Phase 3·NCT05155137·8,518 enrolled
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
Recruiting·CCereMark Pharma, LLC·Phase 3·NCT06254469·230 enrolled
A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
Recruiting·KKeymed Biosciences Co.Ltd·Phase 1·NCT06619613·48 enrolled
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Recruiting·UUniversity of California, Irvine·Phase 2·NCT06580002·51 enrolled
Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy
Recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT07193277·220 enrolled
EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment
Recruiting·PPoitiers University Hospital·N/A·NCT05790707·120 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)